{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:59:40Z","timestamp":1782187180843,"version":"3.54.5"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,3,5]],"date-time":"2002-03-05T00:00:00Z","timestamp":1015286400000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p> <jats:bold>BACKGROUND: <\/jats:bold>HES solutions provide a sterile, alternative colloidal fluid to albumin solutions and\/or plasma in the management of patients who need plasma volume expansion. Solutions of HES are widely accepted internationally but are used only modestly in the United States, largely because of concerns over hemostasis.<\/jats:p><jats:p> <jats:bold>STUDY DESIGN AND METHODS: <\/jats:bold>A randomized, blinded, two\u2010arm trial comparing the hemostatic effects of pentastarch versus hetastarch when infused in the clinically relevant dose of 90 g of HES dissolved in 1.5 L of saline was conducted. Multiple studies of fibrin clot formation, fibrinogen\/fibrinolysis, and platelet (PLT) functions were performed before and on multiple occasions for 70 days following HES infusion.<\/jats:p><jats:p> <jats:bold>RESULTS: <\/jats:bold>Several significant abnormalities of hemostasis assay results occurred following HES infusions, with hetastarch causing significantly greater abnormalities than pentastarch. Individual clotting proteins and blood PLTs fell modestly because of plasma volume expansion and hemodilution. A fall in excess of that caused by hemodilution was demonstrated for von Willebrand factor antigen plus its associated FVIII and ristocetin cofactor activities. The partial thromboplastin time was prolonged, whereas the thrombin time was shortened. Plt function abnormalities were seen in most subjects to a modest degree. Studies of fibrinolysis were normal.<\/jats:p><jats:p> <jats:bold>CONCLUSIONS: <\/jats:bold>Solutions of hetastarch produce significant abnormalities of some hemostasis laboratory results when infused at clinically relevant doses, but it is unlikely that the modest hemostatic abnormalities produced at these doses per se would lead to clinical bleeding. Hetastarch causes greater hemostatic abnormalities than pentastarch, and because both HES solutions have comparable plasma volume\u2010expanding effects, it is reasonable to prefer pentastarch as a plasma volume expander.<\/jats:p>","DOI":"10.1046\/j.1537-2995.2002.00003.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T22:48:47Z","timestamp":1047509327000},"page":"27-36","source":"Crossref","is-referenced-by-count":92,"title":["A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch"],"prefix":"10.1111","volume":"42","author":[{"given":"Ronald\u2003G.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly\u2003J.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David\u2003C.","family":"Stump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,3,5]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0888-6296(88)80004-8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198005000-00007"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198311000-00001"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1983.01390070016004"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198905000-00003"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1997)12:3<146::AID-JCA8>3.3.CO;2-H"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1997)12:4<165::AID-JCA2>3.0.CO;2-8"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<114::AID-JCA2>3.0.CO;2-8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-5223(19)39512-1","article-title":"Hydroxyethyl starch in priming fluid for cardiopulmonary bypass.","volume":"84","author":"Sade RM","year":"1982","journal-title":"J Thorac Cardiovasc Surg"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-5223(19)38727-6","article-title":"A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass.","volume":"89","author":"Sade RM","year":"1985","journal-title":"J Thorac Cardiovasc Surg"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-5223(19)34780-4","article-title":"The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. A randomized clinical trial.","volume":"104","author":"London MJ","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(10)60907-1"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198312000-00009"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800750717"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0022-5223(19)34525-8","article-title":"A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations.","volume":"97","author":"London MJ","year":"1989","journal-title":"J Thorac Cardiovasc Surg"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb03963.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050833"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1996.36596282590.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649964"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1988.28388219155.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25485273815.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25385219903.x"},{"key":"e_1_2_5_24_2","first-page":"556","article-title":"Effect of hydroxyethyl starch on the structure of thrombin\u2010 and reptilase\u2010induced fibrin gels.","volume":"108","author":"Carr ME","year":"1986","journal-title":"J Lab Clin Med"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0888-6296(88)80005-X"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(96)01071-5"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1995.82.1.0044"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1988.tb09021.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199011000-00006"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602969500100307"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197207272870401"},{"key":"e_1_2_5_32_2","first-page":"92","volume-title":"Thrombosis and bleeding disorders: therapy and methods","author":"Rizza CR","year":"1971"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/62.6.856"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655470"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(66)90246-6"},{"key":"e_1_2_5_36_2","first-page":"152","article-title":"Determination of the von Willebrand's disease antigen (factor VIII\u2010related antigen) in plasma by quantitative immunoelectrophoresis.","volume":"86","author":"Zimmerman TS","year":"1975","journal-title":"J Lab Clin Med"},{"key":"e_1_2_5_37_2","first-page":"318","article-title":"Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.","volume":"85","author":"Allain JP","year":"1975","journal-title":"J Lab Clin Med"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(52)90121-5"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(63)90080-9"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(84)90018-5"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1660097"},{"key":"e_1_2_5_42_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0038-1661693","article-title":"Measurement of urokinase\u2010type plasminogen activator (u\u2010PA) with an enzyme\u2010linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.","volume":"56","author":"Darras V","year":"1986","journal-title":"Thromb Haemost"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-131-33998"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(76)90229-2"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(82)90012-3"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(83)80012-6"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2002.00003.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2002.00003.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T16:32:25Z","timestamp":1694363545000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1537-2995.2002.00003.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1046\/j.1537-2995.2002.00003.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1537-2995.2002.00003.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}